38. OA_Abhishek_2_3_32
نویسندگان
چکیده
Background: A thorough understanding of the Rheumatic Heart disease is important to aid in the management of patients with RHD. We hereby thus study various presentations, distributions, clinical profile of various types of valvular involvement in patients with RHD, complications of RHD such as heart failure, arrhythmias, chamber dilation, thromboembolic manifestation, pulmonary hypertension etc. Methods: Total 100 patients of age more than 12 years with Rheumatic heart disease attending medicine and cardiology department were enrolled and studied for demographic details, clinical presentation and complications. Results: Most common age of presentation of valvular heart disease was 21-30 years (41%) with females (57%) preponderance. Mitral valve involvement was the most common (72%), while tricuspid & pulmonary valve involvements were rare. Mitral stenosis 33%) was the most common valvular lesion followed by mitral stenosis with mitral regurgitation. Conclusion: Each valvular lesion in Rheumatic heart disease presented with varied demographic characteristics with peculiar clinical presentation and complication rate.
منابع مشابه
Molecular docking analysis and determination of minimum inhibition concentration of VIM-38/R228S
Objective: The aim of this study was to determine the effects of residues at 228th positions of VIM-38 on minimum inhibition concentration (MIC) and molecular docking analysis. Materials and methods: blaVIM-38 gene was cloned into expression vector pET100/D-TOPO. Then pET100/D-TOPO-VIM-38 was used to generate the R228S mutation by site-directed mutagenesis. The mutant was transformed into E. co...
متن کاملInvestigation into the Efficacy of Val-SN-38, a Valine-Ester Prodrug of the Anti-Cancer Agent SN-38
We recently reported that Val-SN-38, a novel valine ester prodrug of SN-38, had greatly improved the intracellular accumulation of SN-38 in MCF-7 cell line, probably through enhanced uptake via amino acid transporters. In the present study, the efficacy of Val-SN-38 was further investigated both in vitro and in vivo. It was found that the in vitro cytotoxic effect of Val-SN-38 was similar to th...
متن کاملIn vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes
7-Ethyl-10-hydroxycamptothecin (SN-38) is a potent broad-spectrum antitumor drug derived from irinotecan hydrochloride (CPT-11). Due to its poor solubility and instability of the active lactone ring, its clinical use is significantly limited. As one of the most promising formulations for poorly water-soluble drugs, nanocrystals have attracted increasing attention. In order to solve these proble...
متن کاملIdentification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin.
125I-Pituitary adenylate cyclase-activating polypeptide (PACAP) 1-38 is able to bind a factor in human plasma, which can be displaced by unlabelled PACAP 1-38 and PACAP 28-38 but not by the other biologically active form, PACAP 1-27. Likewise, 125I-PACAP 28-38 binds this plasma factor, whereas 125I-PACAP 1-27 does not. Apparent Kd values were measured to be 12.0+/-1.3 and 3.4+/-1.5 nM for PACAP...
متن کاملCombination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Irinotecan is one of the effective anticancer agents for small-cell lung cancer (SCLC) and 7-ethyl-10-hydroxy-campthothecin (SN-38) is an active metabolite of irinotecan. Gefitinib and imatinib are tyrosine kinase inhibitors which have clinical activities in several malignancies and they are also potent inhibitors of breast cancer resistance protein (BCRP) transporter, which confers the resista...
متن کامل